The selective 5-HT1A receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats

@article{Kline2001TheS5,
  title={The selective 5-HT1A receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats},
  author={Anthony E. Kline and J. H. Yu and Ervin Horv{\'a}th and Donald W. Marion and C E Dixon},
  journal={Neuroscience},
  year={2001},
  volume={106},
  pages={547-555}
}
Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.
TLDR
Data indicate that BUS has a narrow therapeutic dose response, and that 0.3 mg/kg is optimal for enhancing spatial learning and memory in this model of TBI.
Neuroprotective Efficacy of Repinotan HCl, a 5-HT1A Receptor Agonist, in Animal Models of Stroke and Traumatic Brain Injury
  • F. Mauler, E. Horváth
  • Medicine, Biology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2005
TLDR
The favorable neuroprotective efficacy, broad dose–response curve, and prolonged therapeutic window observed in all models strongly suggest that repinotan is a promising candidate for treating acute ischemic stroke in humans.
NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury
TLDR
Impairment in learning and memory in TBI animals could be repaired by treatment with MK-801, which could significantly inhibit the degeneration and apoptosis of neurons in damaged brain areas.
A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke.
TLDR
The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of the drug.
Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.
TLDR
It is suggested that a combined therapeutic regimen of 8-OH-DPAT and EE reduces TBI-induced ChAT(+) cell loss, but does not enhance hippocampal cell survival or neurobehavioral performance beyond that of either treatment alone.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Protective effect of MK801 in experimental brain injury.
TLDR
Findings support existing evidence that pharmacological intervention with NMDA receptor antagonist after head injury may be of clinical value in the management of head-injured patients and demonstrate neuroprotective properties of MK801, as expressed in two different variables--reduced edema formation and improved neurological recovery after HT.
The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat.
TLDR
A new forebrain-selective polyamine site NMDA antagonist is evaluated in a rat subdural hematoma (SDH) model and has shown a magnitude of neuroprotection which is comparable with that seen with "first-generation" NMDA antagonists such as MK801, D-CPP-ene and CGS19755.
Effect of prior receptor antagonism on behavioral morbidity produced by combined fluid percussion injury and entorhinal cortical lesion
TLDR
The results suggest that, unlike fluid percussion TBI alone, behavioral impairment may require more select intervention when deafferentation is part of the head trauma pathology.
Effect of Noncompetitive Blockade of N‐Methyl‐d‐Aspartate Receptors on the Neurochemical Sequelae of Experimental Brain Injury
TLDR
The results suggest that excitatory amino acid neurotransmitters may be involved in the pathophysiological sequelae of traumatic brain injury and that noncompetitive N‐methyl‐d‐aspartate receptor antagonists may effectively attenuate some of the potentially deleterious neurochemical sequelAE of brain injury.
Glutamate antagonism during secondary deafferentation enhances cognition and axo‐dendritic integrity after traumatic brain injury
TLDR
Cognitive deficits produced by head trauma involving both neuroexcitation and deafferentation can be attenuated with chronic application of glutamatergic antagonists during the period of de Afferentation injury and that this attenuation is correlated with axo‐dendritic integrity is suggested.
Behavioural and Morphological Outcome of Mild Cortical Contusion Trauma of the Rat Brain: Influence of NMDA-Receptor Blockade
TLDR
NMDA-receptor blockade improved the outcome assessed by the functional tests but failed to influence the morphological changes, suggesting that this behavioural test is a more sensitive indicator of outcome after mild traumatic brain injury (TBI).
...
1
2
3
4
5
...